Paradigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
|
|
- Steven McDowell
- 5 years ago
- Views:
Transcription
1 Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor
2 Disclosure No financial interests related to the subject matter of this talk This presentation includes the off-label use of some medications such as Bevacizumab (Avastin ) and Triamcinolone (Kenacort )
3 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
4 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
5 The Diabetes Epidemic Significant increase in the incidence of diabetes during the last 20 years Increase across all regions, demographic groups, ages, genders, racial/ethnic groups and subpopulations 800,000 new cases/year in US
6
7 1921: Discovery of Insulin: DM became a disease you can live with
8 With the era of insulin, we moved from the era of diabetic coma to the era of diabetic complications. -- Elliott P. Joslin, 1931
9 Prevalence of Diabetes Persons over 20 Years of Age Percent Age (years)
10 Vision Loss From Diabetic Retinopathy Vitreous Hemorrhage Traction Retinal Detachment Diabetic Macular Edema
11 Diabetic Macular Edema and Proliferative Diabetic Retinopathy Prevalence in Lebanon In a recent study, Diabetes Mellitus (DM) prevalence was reported to be around 15.8% in the greater Beirut area. DR reported to be present in 35% of the DM population. 9% having proliferative disease 8% having macular edema.
12 Diabetic Retinopathy Prevalence in Lebanon
13 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
14 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
15 Imaging of DR Stereo Fundus Images
16 Imaging Fluoresceine Angiography
17 Imaging Wide field fundus photography and fundus angiography
18 Imaging Optical Coherence Tomography
19 OCT angiography Imaging
20 Diabetic Retinopathy Clinical Research Network DRCR.net: Dedicated to multicenter clinical research of diabetic retinopathy, macular edema & associated disorders
21 DRCR Network Overview Funding: National Eye Institute-sponsored cooperative agreement initiated September 2002 Objective: The development of a collaborative network to facilitate multicenter clinical research on diabetic retinopathy, diabetic macular edema and associated conditions.
22 DRCR Network Sites DRCR.net >150 sites overall >90 communities >450 total PIs >1000 study personnel 40 States
23 DRCR DME and PDR studies Randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for DME Evaluation of vitrectomy for DME Observational study of development of DME following scatter laser photocoagulation Subclinical DME study Avastin/ Lucentis / Eylea studies for DME Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for PDR Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Intravitreal Saline for Vitreous Hemorrhage from PDR Prompt PRP vs Ranibizumab+Deferred PRP for PDR Study
24 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
25 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
26 Sheikh Zayed Road, 1990 Sheikh Zayed Road, 2005
27 Sheikh Zayed Road, 1990
28 One of the first randomized trials to establish the benefits of laser for DME Standard of care Focal/Grid laser for CSME Risk of moderate visual loss by 50% or more Improvement of VA by 3 lines was uncommon (<3%)
29 ETDRS Laser Treatment for CSME 1 year 50% reduction in visual loss 3 years 66% reduction in visual loss
30 Limitations of Laser Rx: ETDRS (1985) VA rarely improved to => 20/40 Only 3% of pts improved >3 lines of VA (36 months after Rx) Eyes with advanced retinopathy or diffuse ME responded less well No benefit was demonstrated in pts with non-csme
31 Ablative therapy Pharmacotherapy Zayed Rd 2003
32 Steroids Potent anti-inflammatory, anti-permeability and anti-angiogenesis effects Administer topically, peribulbar or into the vitreous cavity Triesence (Alcon) Trivaris (Allergan)
33 Peribulbar Triamcinolone With and Without Focal Laser for Mild DME No significant difference in VA and retinal thickness in all treatment arms at end Steroid caused elevated intra ocular pressure, lid ptosis DRCR Network. Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema A Pilot Study. Ophthalmology Jun;114(6):
34 Intravitreal Triamcinolone (IVTA) Initial trials show significant improvement in DME and visual acuity Large trial 2 years 4mg IVTA vs. Sham Half the risk of further loss 56% gained 5 letters vs. 26% placebo Gillies, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2006; 113:
35 Intravitreal Triamcinolone (IVTA) However. Required repeat injections 68% had increase > 5mm Hg in IOP 55% needed cataract surgery One case of infectious endophthalmitis
36 Three-Year Follow-up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intreavitreal Triamcinolone for DME. DRCR Network (Arch Ophthalmol/vol127(No.3)Mar 2009) Objective: To Evaluate 1mg & 4mg doses of IVTA v/s Focal/Grid for DME Design: Prospective, randomized clinical trial Participants: A total of 306 eyes with DME
37 Focal/Grid Photocoagulation Vs IVTA DME visual loss VA 20/32-20/320 OCT =>250um CSF Laser Focal/Grid 1mg IVTA 4mg IVTA 4 month FU VA was the Primary outcome measure
38 Focal/Grid Photocoagulation Vs IVTA Laser Focal/Grid 1mg IVTA 4mg IVTA Change in VA letter score from baseline 3 yrs Worsening VA =>10 letters from baseline 3 yrs 12% 26% 22%
39 Focal/Grid Photocoagulation Vs Intreavitreal Triamcinolone Conclusion: 1. No long-term benefit of IVTA vs focal/grid Lx in pts with DME 1. Initial response of steroid did not persist 2. Most eyes receiving 4 mg of TA as given in this study are likely to require cataract surgery
40 Summary: Steroids for DME 1. Modest role for DME 2. Extensive ocular side effects 1. May be of value in a specific subset of patients: 1. pseudophakic 2. poor responders to other therapy
41 Intravitreal Steroid Pre Post
42 Vascular Endothelial Growth Factor (VEGF) Elevated intraocular levels in diabetic retinopathy VEGF-A levels Elevated in eyes with DME Higher in eye with extensive leakage than minimal leakage Implicated in the breakdown of blood-retina barrier Increases vascular permeability
43 Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:
44 Macugen Intravitreal injection of pegaptanib for DME Gain in VA of 10 letters in 34% vs. 10% control Mean central retinal thickness decreased by 68µm with 0.3mg versus increase of 4µm with sham Decreased necessity for focal laser (25% vs. 48%) Cunningham, et al. A phase II randomized double-masked trial of pegaptanib for diabetic macular edema. Ophthalmology Oct; 112(10):
45 Avastin Primary Treatment Studies suggest significant improvement in visual acuity and macular thickness
46 Avastin: DRCR net Phase II trial with intravitreal Bevacizumab (Avastin) and/or laser outcome at 24 weeks (short term study) 121 eyes 5 groups: Focal 1.25 mg Avastin once at baseline 1.25 mg avastin at base and 6 weeks 1.25 mg avastin at base and 6 weeks with focal at 3 weeks 2.5 mg avastin at base and 6 weeks DRCR Network. A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmology Oct;114(10):
47 Avastin: DRCR net Avastin groups did better than focal for VA and CMT Quicker response than laser No difference between 1.25mg vs. 2.5mg dose Adding focal to avastin did not appear to add much. DRCR Network. A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmology Oct;114(10):
48 Lucentis (Ranibizumab) READ Study (Ranibizumab for Edema of the macula in Diabetes)
49 Two-Year Outcomes of the Ranibizumab for Edema of the macula in Diabetes (READ-2) Study Ophthalmology 2010;117: Design: Prospective, randomized, interventional, multicenter clinical trial Participants: A total of 126 patients with DME
50 0.5 mg RBZ 0, 1, 3, & 5 mth (n=33) Focal/Grid Laser 0 & 3 mth (if needed) (n=34) 0.5 mg RBZ + Laser 0, 3 mth (n=34) Mean improvement in BCVA 6 mth Mean improvement in BCVA 24 mth
51 0.5 mg RBZ 0, 1, 3, & 5 mth (n=33) Focal/Grid Laser 0 & 3 mth (if needed) (n=34) 0.5 mg RBZ + Laser 0, 3 mth (n=34) % pt who gained =>3 lines of 6 mths % pt who gained =>3 lines of 24 mths
52 0.5 mg RBZ 0, 1, 3, & 5 mth (n=33) Focal/Grid laser 0 & 3 mth (=>250um) (n=34) 0.5 mg RBZ + Laser 0, 3 mth (n=34) Primary end 6 mths Mean no. of injections needed during 18-month (6-24)
53 Conclusions: 1.IV RBZ provided benefit for pts with DME for at least 2 years 2. IV RBZ gives a quick and long lasting effect 3.when combined with focal/grid laser Tx: Residual edema (36 months data from ARVO) Frequency of injections
54 Lucentis cases X4 injections X4 injections X4 injections X4 injections
55 Eylea VIVID and VISTA studies 406 and 466 patients were enrolled respectively.
56 Eylea
57 Which is better?
58
59 Diabetic Retinopathy Clinical Research Network Aflibercept, Bevacizumab, or Ranibizumab for DME Supported through a cooperative agreement from the National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health, Department of Health and Human Services EY14231, EY14229, EY018817
60 Study Design Randomized, multi-center clinical trial (89 Sites) Participants meeting all of the following criteria: At least 18 years old Type 1 or type 2 diabetes Study eye meeting all of the following criteria: ~Snellen equivalent visual acuity 20/32 or worse and 20/320 or better Central-involved DME on clinical exam Central subfield (CSF) thickness protocol-defined gender and optical coherence tomography (OCT) machine-specific thresholds No history of an anti-vegf treatment for DME in the past 12 months or any other DME treatment in the past 4 months
61 Mean Change in Visual Acuity Over 2 Years Full Cohort Week Treatment Group Comparison*: Aflibercept vs. Bevacizumab P = 0.02 Aflibercept vs. Ranibizumab P = 0.47 Ranibizumab vs. Bevacizumab P = * P-values adjusted for baseline visual acuity and multiple comparisons
62 62 Mean Change in Visual Acuity Over 2 Years By Baseline Visual Acuity Subgroup
63 Pre-Specified Ocular Adverse Events through 2 Years (Non-Study Eyes Receiving Study Drug) % of eyes with at least 1 event Aflibercept (N = 144) Bevacizumab (N = 134) Ranibizumab (N = 132) No. of injections Endophthalmitis <1% 0 <1% Inflammation 2% <1% 2% Retinal detachment/tear 0 0 2% Vitreous hemorrhage 8% 9% 7% Injection related cataract 1% <1% 0 Intraocular pressure elevation 13% 11% 14% Includes anterior chamber cell/flare, choroiditis, episcleritis, iritis, vitreal cells. Includes intraocular pressure increase 10mmHg from baseline at any visit, intraocular pressure 30 mmhg at any visit, or initiation of intraocular pressure-lowering medications not in use at baseline, or glaucoma surgery. 63
64 Pre-specified APTC* Adverse Events through 2 Years % of pts with at least one event Aflibercept (N = 224) Bevacizumab (N = 218) Ranibizumab (N = 218) Non-fatal MI 3% 1% 3% Non-fatal stroke <1% 3% 5% Global P-Value Vascular death 1% 4% 4% Any APTC Event 5% 8% 12% Pairwise comparisons (adjusted for multiple comparisons): aflibercept-bevacizumab: P = 0.34, aflibercept-ranibizumab: P = 0.047, bevacizumab-ranibizumab: P = Global P-value adjusting for gender, age at baseline, Hemoglobin A1c at baseline, diabetes type, diabetes duration at baseline, insulin use, prior coronary artery disease, prior myocardial infarction, prior stroke, prior transient ischemic attack, prior hypertension, smoking status: P = * Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--i: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. 64 Antiplatelet Trialists' Collaboration. BMJ 1994;308:
65 Summary: Anti-VEGF for DME 1. Important role in DME 2. Also all three showed that roughly 30% of cases develop regression of their DR stage 3. Good safety profile 4. Could be first line therapy
66 Steroid Implants
67 Dexamethazone Implants Ozurdex Injectable, biodegradable intravitreal dexamethasone extended release implant
68 MEAD study: Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema David S. Boyer, MD, Young Hee Yoon, MD, PhD, Rubens Belfort, MD, PhD, Francesco Bandello, MD, Raj K. Maturi, MD, Albert J. Augustin, MD, Xiao-Yan Li, MD, Harry Cui, MS, Yehia Hashad, MD, Scott M. Whitcup, MD Ophthalmology Volume 121, Issue 10, Pages (October 2014) DOI: /j.ophtha Copyright 2014 American Academy of Ophthalmology Terms and Conditions
69 Ophthalmology , DOI: ( /j.ophtha ) Copyright 2014 American Academy of Ophthalmology Terms and Conditions
70 Steroid Implants Retisert Intravitreal fluocinolone acetonide implant: lasts 3 years ($15-$18K) 58% implanted vs. 30% of control eyes had resolution of DME 100% cataract About 90% glaucoma 28% needed filtering procedure 5% explanted Pearson, et al. Flucinolone Acetonide Implant Study Group. Retisert to treat diabetic macular edema. Invest Ophthalmol Vis Sci 2006;47
71 Flucinolone acetonide Implant: (Illuvien): FAME Trial 0.5 mcg/d implant (n=393) 0.2 mcg/d implant (n=375) Sham injection (n=185) Mean improvement in BCVA 24 mth Campochiaro PA et al. The FAME study. Ophthalmol 2011;118:
72 Flucinolone acetonide Implant: (Illuvien): FAME Trial 0.5 mcg/d implant (n=393) 0.2 mcg/d implant (n=375) Sham injection (n=185) Percent improvement of 15 or more letters in 24 mth % cataract 30-40% glaucoma Up to 7.6% required trabeculectomy Campochiaro PA et al. The FAME study. Ophthalmol 2011;118:
73 FAME A + B: Percentage of Patients With 15-Letter Improvement Over Baseline Primary Readout P = % 28.7% Patients (%) 28.6% 16.2% 27.8% 18.9% P =.018 Months
74 Diabetic Macular Edema: What is the Treatment Paradigm in 2016?
75 General Classification CS-DME Center involving (CMT>250microns) Non-center involving Anti-VEGF agents laser
76 Proposed Classification of DME CS-DME Focal leak Focal thick g Focal leak Diffuse thick g Diffuse non-defined leak Diffuse thickening Diffuse leak Focal thick g laser Laser+ Anti-VEGF agents Anti-VEGF agents laser Ischemic maculopathy Lipid maculopathy
77 Ablative therapy 25 yr experience Outcomes are durable?limitation ETDRS Pharmacotherapy Acknowledging substantial progress?? Long-term results?? to be answered DRCR net Read 2 study VIVID/ VISTA trials Exact RX and regimen will need to be tailored to individual patients
78 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
79 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
80 Panretinal Laser Photocoagulation Benefits: Suppression of severe visual loss 50% reduction in all patients 96% reduction in patients approaching high-risk stage 98% reduction when combined with vitrectomy and glycemic control Suppression of retinal leakage 40% reduction in moderate visual loss Noninvasive, outpatient
81 Panretinal Laser Photocoagulation Drawbacks: Destroys retina in an attempt to maintain vision Side Effects: Peripheral and night vision loss Changes in color vision Complications: Cornea, iris, lens, fovea burns; choroidal, vitreous hemorrhage, epiretinal membranes/traction
82 Potential Complications of Laser Photocoagulation PRP through the Macula Laser Burn to Fovea Laser-induced Bruchs Puncture PRP-induced Lenticular Burns
83 Ablative therapy Pharmacotherapy Zayed Rd 2003
84 The Diabetic Retinopathy Clinical Research Network Prompt PRP vs. Ranibizumab + Deferred PRP for PDR Study Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services EY14231, EY14229, EY
85 10 Letter Score Improvement* N = 104 N = *Baseline VA 20/32 or worse N = 81 N = 86
86 10 Letter Score Worsening P= # 86
87 15 Letter Score Worsening 2-Year Adjusted Difference: -2% 95% Confidence Interval: (-8%, +3%) 87 N = 191 N = 203 N = 160 N = 168
88
89 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
90 Objectives DR epidemiology Review the recent developments in imaging and studying Diabetic Retinopathy. Review the treatment options for Diabetic Macular Edema (DME). Review the treatment options for Proliferative Diabetic Retinopathy (PDR). Take a look into the future.
91
92
93
94 An ARVO 2011 presentation from NYU Compared 0.5 mg versus 1 mg lucentis for DME 3 initial monthly injections followed by PRN However, the PRN was at 2 monthly intervals The 1 mg group did best but the numbers were too small to conclude A 2 mg group was then added Increasing the dose to 2 mg did not improve the outcome Conclusion: the number of PRN injections may be reduced by studying a 1mg dose in trial settings
95 Oral Medications Ruboxistaurin Protein Kinase C (PKC) Beta inhibitor Reduces permeability of the blood-retinal barrier PKC-DME Trial No significant effect on progression to sightthreatening DME or need for focal laser Secondary analysis Reduced progression of DR vs. placebo (p=.054) PKC-DMES Study group. Effect of ruboxistaurin in patients with diabetic macular edema. Arch Ophthal 2007; 125:
96 Anti-TNF Miscellaneous Infliximab is a chimeric IgG1 monoclonal antibody used to treat inflammatory conditions Launching Phase III trial of infliximab for DME Surgical removal of massive macular hard exudate combined with intravitreal triamcinolone in diabetic maculopathy Eye (2007) 21, Intravitreal Microplasmin: inducing PVD to treat DME A Phase 2 Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin for Treatment of Patients With DME (ThromboGenics) Recently FDA approved Miropulse laser: subthreshold micropulsed diode laser burns (each laser application= micropulses, 2ms apart) Promising data from clinical trials so far
97 Failed Oral Medications Aspirin No effect on diabetic retinopathy Ticlopidine Decreased MA s but adverse reactions Sorbinil No effect Astemizol (Antihistamine) No effect Fenofibrate/Clofibrate No effect on DME Octreotide Decreased DR and high-risk DR progression (Thyroxine replacement needed in all treated patients)
98 Conclusion Prompt Referral to an ophthalmologist for diagnosis and treatment of DME and PDR is important. Controlling systemic factors Treatment should be individually tailored according to patients.
99 Our secret weapons remain
Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationCURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT. Muge R. Kesen, MD
CURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT Muge R. Kesen, MD No relevant financial interest or relationships DISCLOSURE OBJECTIVES Current trends (evidence based) Review of clinical trials Diabetic
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationDiabetic retinopathy (DR) progressively
FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationRecalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk Version 4.0 September 19, 2017 Anti-VEGF
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationDiabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*
EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY* Lloyd Paul Aiello, MD, PhD, and Jennifer K. Sun, MD, MPH ABSTRACT There is a wide array of research into the pathophysiology and treatment
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol
More informationDiabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
More informationORIGINAL RESEARCH ARTICLE
EJO ISSN 1120-6721 Eur J Ophthalmol 2017; 27 (3): 357-362 DOI: 10.5301/ejo.5000929 ORIGINAL RESEARCH ARTICLE Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Version
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationAnti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab,
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationNew developments in the treatment of diabetic macular edema: latest clinical evidence
Review: Clinical Trial Outcomes New developments in the treatment of diabetic macular edema: latest clinical evidence Clin. Invest. (2012) 2(1), 89 105 Diabetic retinopathy is a major cause of blindness
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Short-term Evaluation of Combination Corticosteroid+Anti- VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationDiabetic Macular Oedema To treat or not to treat?
Diabetic Macular Oedema To treat or not to treat? Ms Ranjit Sandhu MBBS MRCOphth MD FRCOphth Consultant Ophthalmic Surgeon Cataract Surgery, Medical Retina & Uveitis The Luton and Dunstable University
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationPast ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control
Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1
More informationCOMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY
Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationEFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Basrah Journal Of Surgery EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA Salah Zuhair Abed Al-Asadi MB,ChB, FICMS, Lecturer, Department of Surgery, College
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 20 Next Review: September 2017 Related Policies 9.03.21 Aqueous Shunts for Glaucoma Intravitreal Corticosteroid Implants Summary An intravitreal implant
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationTreatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth
Treatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth Disclosures and acknowledgements Financial disclosures; Alcon,
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationCombination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.
REVIEW ARTICLE Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U Cindy Ung 1, Kareem Moussa 1, Yoshihiro Yonekawa
More informationIntravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema
Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema Version 6.0 May 21, 2010 Note: See
More informationDiabetic Retinopathy What You Should Know. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute
Diabetic Retinopathy What You Should Know U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute The National Eye Institute (NEI) conducts and supports research
More informationOverview of the Pathogenesis of Diabetic Retinopathy
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationAn updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema
Review Article An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema Jia-Kang Wang 1,2,3,4, Tzu-Lun Huang 1,5, Pei-Yuan Su 1,4,6,
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDexamethasone implant in diabetic macular edema in real-life situations
(2016) 30, 426 430 2016 Macmillan Publishers Limited All rights reserved 0950-222X/16 www.nature.com/eye CLINICAL STUDY 1 Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Institute, Hyderabad,
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationOriginal Effective Date: 10/24/2016. Subject: Intravitreal corticosteroid implants: Ozurdex (dexamethasone intravitreal implant)
Subject: Intravitreal corticosteroid implants: Ozurdex (dexamethasone intravitreal implant) Original Effective Date: 10/24/2016 Policy Number: MCP-282 Revision Date(s): 12/13/2017 DISCLAIMER This Molina
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Version
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationMolecular Biology of Diabetic Retinopathy
Opportunities for Therapeutic Intervention: Molecular Biology of Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and DIABETIC MICROVASCULAR COMPLICATIONS TODAY. Release Date: January 2006.
More informationRetina Diabetic Macular Edema
Retina Diabetic Macular Edema ILUVIEN A New Approach to the Treatment of Diabetic Macula Edema Pravin U Dugel, MD 1 and Richard Parrish, MD 2 1. Retinal Consultants of Arizona, Phoenix, Arizona, US; Clinical
More informationRandomized Trial Evaluating Short- Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular
Randomized Trial Evaluating Short- Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema After Focal/grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal
More informationTargeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice
Targeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice Baruch D Kuppermann, MD, PhD Professor of Ophthalmology and Biomedical Engineering Director,
More informationA Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Diabetic Retinopathy Clinical Research Network A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Version1.2 April 27, 2006 Avastin Protocol 4-27-06 V1.2.doc Contact
More informationIntravitreal Injection
for patients Eye Clinic Ipswich Hospital Tel: 01473 703230 Intravitreal Injection What is an intravitreal injection? An intravitreal injection is the injection of a drug into the vitreous body (the jelly
More informationCharles C. Wykoff MD PhD Rahul N. Khurana MD
HDWallpapers Suprachoroidal Triamcinolone Acetonide with & without Intravitreal Aflibercept for DME: Results of the 6 Month Prospective Phase 1/2 Hulk trial Blanton Eye Institute Charles C. Wykoff MD PhD
More informationSubclinical Diabetic Macular Edema Study
Diabetic Retinopathy Clinical Research Network Subclinical Diabetic Macular Edema Study Version 2.0 March 21, 2006 Subclinical DME Protocol v2 0 3-21-06.doc Table of Contents Chapter 1. Background Information
More informationAn Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry
An Update on Branch Retinal Vein Occlusion Treatment Studies Amiee Ho, O.D. Pacific University College of Optometry Course Description This course focuses on current treatment options available for macular
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationFinancial Disclosures
Financial Disclosures DB is a scientific advisor for Regeneron/ Bayer and Genentech/ Roche & a DB member of the Regeneron Combination Products Steering Committee RCH receives grant support from Regeneron/
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationDiabetic retinopathy (DR) represents a
THE MOLECULAR BIOLOGY OF DIABETIC RETINOPATHY: OPPORTUNITIES FOR THERAPEUTIC INTERVENTION Lloyd P. Aiello, MD, PhD ABSTRACT Hyperglycemia is the principal underlying cause of diabetic microvascular complications,
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationSupplement to March Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG
Supplement to March 2018 Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG Ranibizumab for Visual Impairment in DME: An Overview of The Evidence BY PROF.
More informationFA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences
FA Conference Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences Patient Presentation CC: (sent by optometrist) Blurry/foggy vision HPI: 62 yo
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationFLUOCINOLONE ACETONIDE: STEROID LONG ACTING
FLUOCINOLONE ACETONIDE: STEROID LONG ACTING Giuseppe Querques, MD PhD Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita Salute San Raffaele, Milan, Italy Financial Disclosure ADVISORY
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationUpdates and Controversies
Updates and Controversies Philippine Journal of OPHTHALMOLOGY Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth.
More informationNew Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationDexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):108-114 https://doi.org/10.3341/kjo.2017.31.2.108 Original Article Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory
More informationDiabetic macular edema (DME) is a treatable sequela of diabetic retinopathy and a significant cause of visual morbidity among working
Update on the Management of Diabetic Macular Edema Shawn M Iverson 1 and W Lloyd Clark 1,2 1. Palmetto Health - University of South Carolina Medical Group, Columbia, South Carolina, US; 2. Assistant Clinical
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation Version 1.4 June 24, 2005 PRP Obs Study Protocol
More informationEvolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations
Supplement to January/February 2016 CME ACTIVITY Evolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations John E. Anderson, MD Jay S. Duker, MD Allen C. Ho, MD John W. Kitchens,
More information8/8/17. Objectives. Proliferative Diabetic Retinopathy (PDR) Examining the Diabetic Patient: What Matters Most
Objectives Examining the Diabetic Patient: What Matters Most Jordan Keith, OD, FAAO Minneapolis, MN Simplify strategy for evaluating the eyes of diabetics Identify the threats to vision and treatments
More informationReview Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
Hindawi Ophthalmology Volume 2017, Article ID 2407037, 7 pages https://doi.org/10.1155/2017/2407037 Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
More informationClinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center
More informationDexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema
Dexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema This technology summary is based on information available at the time of research and a limited literature search.
More informationTreatment practice in the
Strategies for managing neovascular AMD and in routine clinical care BY ROD MCNEIL Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal
More information